论文部分内容阅读
目的探讨多药耐药（ＭＤＲ１）Ｐ糖蛋白（Ｐｇｐ）表达在成人初治急性白血病（ＡＬ）中的预后意义。方法采用流式细胞术及单克隆抗体ＵＩＣ２检测了１５１例成人急性髓细胞白血病（ＡＭＬ）、４７例成人急性淋巴细胞白血病（ＡＬＬ）患者的白血病细胞Ｐｇｐ表达。结果Ｐｇｐ＋在ＡＭＬ患者的完全缓解（ＣＲ）率为２０．５％，明显低于Ｐｇｐ患者的７８．５％（Ｐ＜０．００１）；Ｐｇｐ＋在ＡＬＬ患者的ＣＲ率为６６．７％，与Ｐｇｐ－患者的８０％相比，差异无显著性（Ｐ＞０．０５）。Ｐｇｐ＋患者的６个月复发率明显高于Ｐｇｐ患者（ＡＭＬ：６６．７％∶８．７％，Ｐ＜０．００１；ＡＬＬ：５０％∶９．５％，Ｐ＜０．０５）；Ｐｇｐ＋患者的平均无病生存期（ＤＦＳ）较Ｐｇｐ患者短（ＡＭＬ：５个月∶１３个月；ＡＬＬ：４个月∶１３个月）。结论Ｐｇｐ过度表达是成人ＡＬ的不良预后因素，是判断疗效及早期复发的一个重要指标。
Objective To investigate the prognostic significance of multidrug resistance (MDR1) P glycoprotein (P gp) expression in primary adult acute leukemia (AL). Methods Flow cytometry and monoclonal antibody UIC2 were used to detect the expression of Pgp in leukemia cells in 151 adult acute myeloid leukemia (AML) and 47 adult acute lymphoblastic leukemia (ALL) patients. Results The complete remission (CR) rate of Pgp+ in AML patients was 20.5%, which was significantly lower than that of 78.5% of Pgp patients (P<0.001). The CR rate of Pgp+ in ALL patients was 66.7%, compared with 80% of P gp-patients, the difference was not significant (P> 0.05). The 6-month recurrence rate of Pgp+ patients was significantly higher than that of Pgppatients (AML: 66.7%: 8.7%, P<0.001; ALL: 50%: 9.5%, P<0. .05); P gp + patients, the average disease-free survival (DFS) shorter than P gp patients (AML: 5 months: 13 months; ALL: 4 months: 13 months). Conclusion P-gp overexpression is a poor prognostic factor for adult AL and is an important indicator of efficacy and early recurrence.